These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11847403)

  • 41. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
    Ferguson JJ; Wilson JM; Diez J
    Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acute myocardial infarction: early strategies to optimize results.
    J Invasive Cardiol; 2005 May; 17(5):288-91. PubMed ID: 15879613
    [No Abstract]   [Full Text] [Related]  

  • 43. Fibrinolysis for acute myocardial infarction: the future is here and now.
    Armstrong PW; Collen D; Antman E
    Circulation; 2003 May; 107(20):2533-7. PubMed ID: 12777317
    [No Abstract]   [Full Text] [Related]  

  • 44. Facilitated PCI: rationale, current evidence, open questions, and future directions.
    Zimarino M; Sacchetta D; Renda G; De Caterina R
    J Cardiovasc Pharmacol; 2008 Jan; 51(1):3-10. PubMed ID: 18209562
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reperfusion and antithrombotic strategies for acute MI.
    Belli G; Topol EJ
    Contemp Intern Med; 1995 Jul; 7(7):31-8, 43-5. PubMed ID: 10150611
    [No Abstract]   [Full Text] [Related]  

  • 46. Aspirin and its rivals. As your options increase, your choices get harder.
    Harv Mens Health Watch; 2002 Dec; 7(5):1-5. PubMed ID: 12499131
    [No Abstract]   [Full Text] [Related]  

  • 47. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
    Sabatine MS; Morrow DA; Montalescot G; Dellborg M; Leiva-Pons JL; Keltai M; Murphy SA; McCabe CH; Gibson CM; Cannon CP; Antman EM; Braunwald E;
    Circulation; 2005 Dec; 112(25):3846-54. PubMed ID: 16291601
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acute coronary syndromes: new developments in pharmacological treatment strategies.
    Gylys K; Gold M
    Crit Care Nurse; 2000 Apr; Suppl():3-14; quiz 15-6. PubMed ID: 11876169
    [No Abstract]   [Full Text] [Related]  

  • 49. Augmentation of thrombolysis with antiplatelet drugs.
    Coller BS
    Coron Artery Dis; 1995 Dec; 6(12):911-4. PubMed ID: 8814816
    [No Abstract]   [Full Text] [Related]  

  • 50. Aspirin: redundant in users of nonaspirin, nonsteroidal antiinflammatory agents?
    Ray WA; Murray KT
    Am Heart J; 2002 Mar; 143(3):381-2. PubMed ID: 11868040
    [No Abstract]   [Full Text] [Related]  

  • 51. Reperfusion therapy for acute myocardial infarction: drugs or devices? Is this the right question?
    Pavlides GS; Cokkinos DV
    Clin Cardiol; 2004 May; 27(5):254-6. PubMed ID: 15188937
    [No Abstract]   [Full Text] [Related]  

  • 52. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence.
    Topol EJ
    Circulation; 1998 Jan; 97(2):211-8. PubMed ID: 9445175
    [No Abstract]   [Full Text] [Related]  

  • 53. [Pharmacological thrombolysis in acute myocardial infarction. Lessons learned from ISIS-2 and GUSTO-1. I].
    Jerjes-Sánchez C; Garza-Ruiz A; Gutiérrez-Fajardo P
    Arch Inst Cardiol Mex; 1999; 69(5):478-87. PubMed ID: 10640212
    [No Abstract]   [Full Text] [Related]  

  • 54. Myocardial infarction and heparin revisited.
    Conti CR
    Clin Cardiol; 1995 Nov; 18(11):607. PubMed ID: 8590527
    [No Abstract]   [Full Text] [Related]  

  • 55. Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1.
    Armstrong PW; Collen D
    Circulation; 2001 Jun; 103(23):2862-6. PubMed ID: 11401946
    [No Abstract]   [Full Text] [Related]  

  • 56. Myocardial infarction: review of clinical trials and treatment strategies.
    Casey K; Bedker DL; Roussel-McElmeel PL
    Crit Care Nurse; 1998 Apr; 18(2):39-52; quiz 53-4. PubMed ID: 9708119
    [No Abstract]   [Full Text] [Related]  

  • 57. [Clinical aspects of the fibrinolytic therapy of myocardial infarct].
    Sterkowicz S
    Wiad Lek; 1967 Jul; 20(13):1235-9. PubMed ID: 6056528
    [No Abstract]   [Full Text] [Related]  

  • 58. [Summary: Aggregation inhibitors in the prophylaxis of myocardial infarct].
    Walter E; Weber E; Reuter HD
    Internist (Berl); 1980 Jul; 21(7):393. PubMed ID: 7007278
    [No Abstract]   [Full Text] [Related]  

  • 59. The general concepts of an equivalence trial, applied to ASSENT-2, a large-scale mortality study comparing two fibrinolytic agents in acute myocardial infarction.
    Lesaffre E; Bluhmki E; Wang-Clow F; Berioli S; Danays T; Fox NL; Van de Werf F
    Eur Heart J; 2001 Jun; 22(11):898-902. PubMed ID: 11428813
    [No Abstract]   [Full Text] [Related]  

  • 60. Platelet inhibitor therapy: mechanisms of action and clinical use.
    Michelson AD
    J Thromb Thrombolysis; 2003; 16(1-2):13-5. PubMed ID: 14760206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.